156 related articles for article (PubMed ID: 17354232)
1. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL; Meisner BC; Frick KD; Armstrong DK
Cancer; 2007 Apr; 109(8):1513-22. PubMed ID: 17354232
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
3. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis.
Greving JP; Vernooij F; Heintz AP; van der Graaf Y; Buskens E
Gynecol Oncol; 2009 Apr; 113(1):68-74. PubMed ID: 19176236
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis.
Scheetz MH; Bolon MK; Postelnick M; Noskin GA; Lee TA
J Antimicrob Chemother; 2009 Apr; 63(4):816-25. PubMed ID: 19202150
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers.
Porter GA; Cantor SB; Walsh GL; Rusch VW; Leung DH; DeJesus AY; Pollock RE; Brennan MF; Pisters PW
J Thorac Cardiovasc Surg; 2004 May; 127(5):1366-72. PubMed ID: 15115994
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
9. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
10. Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care.
Smith MY; Cromwell J; DePue J; Spring B; Redd W; Unrod M
Manag Care; 2007 Jul; 16(7):48-55. PubMed ID: 17907712
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of a test to detect metastases for endometrial cancer.
Havrilesky LJ; Maxwell GL; Chan JK; Myers ER
Gynecol Oncol; 2009 Mar; 112(3):526-30. PubMed ID: 19100608
[TBL] [Abstract][Full Text] [Related]
13. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
[TBL] [Abstract][Full Text] [Related]
14. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness.
Seidler AM; Bramlette TB; Washington CV; Szeto H; Chen SC
Dermatol Surg; 2009 Nov; 35(11):1776-87. PubMed ID: 19737291
[TBL] [Abstract][Full Text] [Related]
15. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
16. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
Roe RH; Lass JH; Brown GC; Brown MM
Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
19. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
20. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.
Jewell EL; Kulasingam S; Myers ER; Alvarez Secord A; Havrilesky LJ
Gynecol Oncol; 2007 Dec; 107(3):532-40. PubMed ID: 17900674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]